Sentences with phrase «for nuclear factor»

Not exact matches

There could be several factors that had investors on edge — including news that North Korea had completed a fifth nuclear missile test and the European Central Bank had declined to announce additional measures to help stimulate Europe's sluggish economy — but many strategists pointed to a speech Friday morning by Federal Reserve Bank of Boston President Eric Rosengren, in which he said that «a reasonable case can be made» for tightening interest rates in the U.S..

With massive and increasing structural deficits; exploding debt in all sectors; hostile demographics; social and political fracturing and disintegration; grotesque wealth inequality; extraordinary global trade competition; a complete collapse of respect for vital government organizations such as the Justice Department and FBI, which the people now realize have gone rogue; an extremely complex and corrosive global geopolitical environment; the real prospect of war, potentially nuclear and worldwide; not to mention numerous additional factors, we can only point to few other times in history more dangerous to the people's financial welfare, and therefore more overall bullish for gold, one of the only financial sanctuaries proven to work in times of dislocation.

The OAR proposal uses a variation of therapeutic cloning called altered nuclear transfer (ANT) in which the nucleus of a donor cell (a skin cell, for example), containing the 30,000 genes of the genetic code, is altered in such a way that it produces an epigenetic factor, a protein called nanog.

@Chad: I. Mutations in DNA sequences generally occur through one of two processes: A. Environmental factors: DNA damage from environmental agents such as ultraviolet light (sunshine), nuclear radiation or certain chemicals B. Mistakes that occur when a cell copies its DNA in preparation for cell division.

The biggest factor may be if there's a practical lower limit in size for a nuclear weapons program.

«The explanation is, in brief, that in metals, irradiation produces on picosecond time scales a liquid - like zone, which during the cooling - down phase recombines much of the initially produced damage, leading to a factor of 1/3 reduction in damage,» says Professor Kai Nordlund who was in lead of the team on search for more accurate predictions of usability of materials in nuclear environments, that now present their results freshly in Nature Communications.

This risk factor pushes the «levelized» or all - in price of nuclear power from new units to 8.4 cents per kilowatt - hour, the MIT study concludes, versus 6.2 cents for coal - fired plants and 6.5 cents for natural gas generation (if gas is priced at $ 7 per million British thermal units, or roughly 1,000 cubic feet of flowing gas).

This compares with EDF's average load factor for its French nuclear fleet of 73 percent in 2013, which is also down from its highest level of 77.6 percent in 2005, the company's 2013 results show.

By building a physical framework for this motion, we can identify key factors in the nuclear structure and function as well as expand the field of stochastic polymer dynamics.

In collaboration with the University of Texas Southwestern Medical Center (UTSW) in Dallas, the researchers found that the tumor - suppressive activity of geranylgeraniol was accompanied by down - regulation of HMG CoA reductase, a key enzyme in the mevalonate pathway that provides essential intermediates for the posttranslational modification of growth - related proteins such as Ras, nuclear lamins and insulin - like growth factor receptors.

For example, nuclear factor - kappa B (NF - kB) is a complex of proteins that acts as a master switch for turning inflammation genes on and for controlling cell deaFor example, nuclear factor - kappa B (NF - kB) is a complex of proteins that acts as a master switch for turning inflammation genes on and for controlling cell deafor turning inflammation genes on and for controlling cell deafor controlling cell death.

A likely factor is the problem that DNDO has run into with its Advanced Spectroscopic Portal (ASP) program, which was started in 2004 to screen cargo at land and sea borders for signatures of nuclear material.

Working with cultures of respiratory tract cells, Elias's team found that the gene that codes for il - 6 is inactive unless a protein known as nf - kb (nuclear factor - kappa beta) attaches to the gene.

Nuclear radiation ticks all the boxes for increasing the fear factor.

Nuclear factor kappa B in the dorsal raphe of macaques: an anatomical link for steroids, cytokines and serotonin.

Hepatocyte nuclear factor 4α (HNF4α) is a transcription factor required for liver development and the control of expression of liver - specific genes, and it is associated with several critical metabolic pathways [3].

Amo1 is not required for the microtubule loading of several factors affecting microtubule dynamics, and does not seem to be required for nuclear pore function.

For example, an ATPase - and / or helicase - dependent mechanism is essential for RNA helicase A — mediated transactivation function (41) and the functional interaction with nuclear factor κB (4For example, an ATPase - and / or helicase - dependent mechanism is essential for RNA helicase A — mediated transactivation function (41) and the functional interaction with nuclear factor κB (4for RNA helicase A — mediated transactivation function (41) and the functional interaction with nuclear factor κB (42).

The researchers found that patients from MODY3 families had one of several different mutations in the gene for hepatocyte nuclear factor 1 alpha (HNF -1-alpha) but healthy subjects had normal copies of the gene.

Susan Amara, USA - «Regulation of transporter function and trafficking by amphetamines, Structure - function relationships in excitatory amino acid transporters (EAATs), Modulation of dopamine transporters (DAT) by GPCRs, Genetics and functional analyses of human trace amine receptors» Tom I. Bonner, USA (Past Core Member)- Genomics, G protein coupled receptors Michel Bouvier, Canada - Molecular Pharmacology of G protein - Coupled Receptors; Molecular mechanisms controlling the selectivity and efficacy of GPCR signalling Thomas Burris, USA - Nuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transNuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transnuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transNuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transNuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transporters

Abbreviations: Aβ, amyloid β - peptide; AD, Alzheimer's disease; ALS, amyotrophic lateral sclerosis; Ambra1, activating molecule in Beclin -1-regulated autophagy; AMPK, AMP - activated protein kinase; APP, amyloid precursor protein; AR, androgen receptor; Atg, autophagy - related; AV, autophagic vacuole; Bcl, B - cell lymphoma; BH3, Bcl - 2 homology 3; CaMKKβ, Ca2 + - dependent protein kinase kinase β; CHMP2B, charged multivesicular body protein 2B; CMA, chaperone - mediated autophagy; 2 ′ 5 ′ ddA, 2 ′, 5 ′ - dideoxyadenosine; deptor, DEP - domain containing mTOR - interacting protein; DRPLA, dentatorubral pallidoluysian atrophy; 4E - BP1, translation initiation factor 4E - binding protein - 1; Epac, exchange protein directly activated by cAMP; ER, endoplasmic reticulum; ERK1 / 2, extracellular - signal - regulated kinase 1/2; ESCRT, endosomal sorting complex required for transport; FAD, familial AD; FDA, U.S. Food and Drug Administration; FIP200, focal adhesion kinase family - interacting protein of 200 kDa; FoxO3, forkhead box O3; FTD, frontotemporal dementia; FTD3, FTD linked to chromosome 3; GAP, GTPase - activating protein; GR, guanidine retinoid; GSK3, glycogen synthase kinase 3; HD, Huntington's disease; hiPSC, human induced pluripotent stem cell; hVps, mammalian vacuolar protein sorting homologue; IKK, inhibitor of nuclear factor κB kinase; IMPase, inositol monophosphatase; IP3R, Ins (1,4,5) P3 receptor; I1R, imidazoline - 1 receptor; JNK1, c - Jun N - terminal kinase 1; LC3, light chain 3; LD, Lafora disease; L - NAME, NG - nitro - L - arginine methyl ester; LRRK2, leucine - rich repeat kinase 2; MIPS, myo - inositol -1-phosphate synthase; mLST8, mammalian lethal with SEC13 protein 8; MND, motor neuron disease; mTOR, mammalian target of rapamycin; mTORC, mTOR complex; MVB, multivesicular body; NAC, N - acetylcysteine; NBR1, neighbour of BRCA1 gene 1; NOS, nitric oxide synthase; p70S6K, ribosomal protein S6 kinase - 1; PD, Parkinson's disease; PDK1, phosphoinositide - dependent kinase 1; PE, phosphatidylethanolamine; PI3K, phosphoinositide 3 - kinase; PI3KC1a, class Ia PI3K; PI3KC3, class III PI3K; PI3KK, PI3K - related protein kinase; PINK1, PTEN - induced kinase 1; PKA, protein kinase A; PLC, phospholipase C; polyQ, polyglutamine; PS, presenilin; PTEN, phosphatase and tensin homologue deleted from chromosome 10; Rag, Ras - related GTP - binding protein; raptor, regulatory - associated protein of mTOR; Rheb, Ras homologue enriched in brain; rictor, rapamycin - insensitive companion of mTOR; SBMA, spinobulbar muscular atrophy; SCA, spinocerebellar ataxia; SLC, solute carrier; SMER, small - molecule enhancer of rapamycin; SMIR, small - molecule inhibitor of rapamycin; SNARE, N - ethylmaleimide - sensitive factor - attachment protein receptor; SOD1, copper / zinc superoxide dismutase 1; TFEB, transcription factor EB; TOR, target of rapamycin; TSC, tuberous sclerosis complex; ULK1, UNC -51-like kinase 1; UVRAG, UV irradiation resistance - associated gene; VAMP, vesicle - associated membrane protein; v - ATPase, vacuolar H + - ATPase; Vps, vacuolar protein sorting

Aug. 23, 2017 - In the event of an accidental radiological release from a nuclear power plant reactor or industrial facility, tracing the aerial plume of radiation to its source in a timely manner could be a crucial factor for emergency responders, risk assessors and investigators.

Nuclear Activity of ROXY1, a Glutaredoxin Interacting with TGA Factors, Is Required for Petal Development in Arabidopsis thaliana.

One particularly bad guy in high amounts is the inflammatory nuclear factor kappa B, or NF - kB for short.

It works by activating the inflammatory nuclear factor kappa B (NF - kB for short), which binds to your DNA and triggers a number of inflammatory cascades throughout the body.

It does so by reducing the thermostat for inflammation called nuclear factor kappa beta.

And yes central power will be another piece (nuclear is great for baseload power... it operates at 90 % capacity factors even if the price of building a new plant has risen by 130 % since 2000) Centralized wind and solar will mature but then there's the transmission issue...

Well, the actual problem is that the externalities for that cheap fossil and nuclear fuel (not to mention gov subsidies and tax breaks) have not been factored in.

Unlike with wind and solar, large volumes of cooling water are a necessity for nuclear power generation, which should also be factored into the costs.

In sum, the risk is not zero, and the multiplicative dread - to - risk factor is large for nuclear power risks.

[D] espite additions of substantial wind, solar, and nuclear capacity, when properly adjusted for capacity factor (the amount of annual energy produced per unit of capacity) to reflect production capability, the amount of new coal energy added to the China grid last year exceeded new solar energy by 17 times, new wind energy by more than 4 times, and even new hydro by more than 3 times.

They agree with me in such statements as «'' A critical factor for the future of an expanded nuclear power industry is the choice of the fuel cycle — what type of fuel is used, what types of reactors «burn» the fuel, and the method of disposal of the spent fuel.

The Nuclear Energy Institute (NEI), echoing trade groups that lobby for other fuel sources including coal and gas, has said that a key factor for several premature retirements is the failure of RTO markets to value attributes of nuclearNuclear Energy Institute (NEI), echoing trade groups that lobby for other fuel sources including coal and gas, has said that a key factor for several premature retirements is the failure of RTO markets to value attributes of nuclearnuclear power.

The 2,301 megawatt (MW) Vogtle nuclear plant has a 95 % capacity factor for each hour of the day (purple line).

Nuclear power requires less expensive transmission (shorter distances and smaller transmission capacity in total because the capacity needs to be sufficient for maximum output but intermittent renewables average around 10 % to 40 % capacity factor whereas nuclear averages around 80 % toNuclear power requires less expensive transmission (shorter distances and smaller transmission capacity in total because the capacity needs to be sufficient for maximum output but intermittent renewables average around 10 % to 40 % capacity factor whereas nuclear averages around 80 % tonuclear averages around 80 % to 90 %).

And you've made no allowance for learning rates and the potential for nuclear power to reduce costs (e.g. from a factor of 100 improvement in fuel efficiency).

Nuclear power would provide many other benefits as well: energy security, reliable energy supply, reduce shipping costs and energy used in shipping coal by a factor of 20,000 to 2 million, provide fresh water, no need for carbon pricing, avoid 1 million fatalities per year by 2050,... https://judithcurry.com/2012/08/17/learning-from-the-octopus/#comment-231867.

Whether or not nuclear generation has truly peaked will depend on a number of factors, including how many Japanese reactors resume operation, how many licenses are extended for aging reactors worldwide, and the pace and magnitude of uprating existing units.

Critics argue, for example, that a wind turbine farm can only operate at a «capacity factor» (a ratio that measures the potential output of an energy source against its actual output) of 30 to 35 percent, while a nuclear reactor operates at around 90 percent.

Assuming the same capacity factor (75 %) for our new nuclear plant, that would give us 105 TWh and 91,304 jobs.

-- Muller believes humans are changing climate with CO2 emissions — humans have been responsible for «most» of a 0.4 C warming since 1957, almost none of the warming before then — IPCC is in trouble due to sloppy science, exaggerated predictions; chairman will have to resign — the «Climategate» mails were not «hacked» — they were «leaked» by an insider — due to «hide the decline» deception, Muller will not read any future papers by Michael Mann — there has been no increase in hurricanes or tornadoes due to global warming — automobiles are insignificant in overall picture — China is the major CO2 producer, considerably more than USA today — # 1 priority for China is growth of economy — global warming is not considered important — China CO2 efficiency (GDP per ton CO2) is around one - fourth of USA today, has much room for improvement — China growth will make per capita CO2 emissions at same level as USA today by year 2040 — if it is «not profitable» it is «not sustainable» — US energy future depends on shale gas for automobiles; hydrogen will not be a factor — nor will electric cars, due to high cost — Muller is upbeat on nuclear (this was recorded pre-Fukushima)-- there has been no warming in the USA — Muller was not convinced of Hansen's GISS temperature record; hopes BEST will provide a better record.

Exelon's CEO Chris Crane called for a similar recommendation in an interview with UtilityDive earlier this year: «[Nuclear] provides more benefits than just megawatts... The resiliency, fuel diversity — it's important that is factored into price formation.»

Nevertheless, as shown in the figure, these combined capacity factors for wind and solar are far less than those for the dispatchable technologies — natural gas, coal, and nuclear.

«Nuclear power is one of the chief long - term hopes for conservation... Cheap energy in unlimited quantities is one of the chief factors in allowing a large rapidly growing population to preserve wildlands, open space, and lands of high scenic value... With energy we can afford the luxury of setting aside lands from productive uses.»

As an example, the 1,532 MW of emissions - free Bruce Nuclear refurbished generation, at a capacity factor of 90 % supplying 12.08 TWh, easily covered the loss of 4.1 TWh of coal - fired generation and left 8.7 TWh for added demand due to its flexibility to steam off or bypass the turbines.

The indicators emissions per capita, emissions per GDP and CO2 / kWh are adjusted as if the generation of electricity from nuclear power had produced 350 gCO2 / kWh (emission factor for natural gas).

But just how much renewables, nuclear, and gas will mix to make up for the coming coal retirements will depend on a number of variables, including economic factors and whether the CPP goals are extended to 2040.

The indicators «emissions per capita», «emissions per GDP» and «CO2 per kWh electricity» for all countries have therefore been adjusted as if the generation of electricity from nuclear power had produced 350 gCO2 / kWh (emission factor for natural gas).

But he wholly fails to explain what the implications of the variability problem is (the need for overbuild of generation capacity and expensive / unfeasible large - scale energy storage), nor whether, if an effort is made to deal practically with these problems in real national electricity grids, the «increasingly cheaper» renewables will ever become cheap enough (when all relevant real - world factors are considered) and reliable enough (without natural gas «backup»), to actually substitute for and displace fossil fuels (or nuclear) at the scale required.

In the spot market for electricity, if the renewables have gone AWOL, then nuclear electricity may command a higher price offsetting a lower capacity factor to some extent.